Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21718781 | 0.76 | NUDT1 (0.36) | L3MBTL1SRCNUDT1KDM4EHTT | |
| SCHEMBL2658965 | 0.75 | NUDT1 (0.39) | L3MBTL1SRCNUDT1DYRK1A | |
| SCHEMBL30833161 | 0.75 | NUDT1 (0.39) | L3MBTL1SRCNUDT1DYRK1A | |
| SCHEMBL13229296 | 0.75 | AXL (0.46) | L3MBTL1SRCNUDT1DYRK1A | |
| SCHEMBL24521477 | 0.75 | NUDT1 (0.39) | L3MBTL1SRCNUDT1DYRK1A | |
| SCHEMBL23114458 | 0.75 | NUDT1 (0.35) | L3MBTL1SRCNUDT1HTT | |
| SCHEMBL15158580 | 0.75 | NUDT1 (0.35) | L3MBTL1SRCNUDT1 | |
| SCHEMBL30835289 | 0.73 | NUDT1 (0.38) | L3MBTL1SRCNUDT1DYRK1A | |
| SCHEMBL14635679 | 0.71 | SRC (0.51) | L3MBTL1SRCNUDT1CYP2E1CYP2A6 | |
| SCHEMBL23691866 | 0.71 | SRC (0.33) | L3MBTL1SRCNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3555070-B1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3596072-B1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-06-22 | — | — | EP | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210087189-A1 | SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| US-9550786-B2 | 4-fluoropiperidine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150322074-A1 | 4-FLUOROPIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | US | disclosed |
| US-9126943-B2 | Nitrogenated heterocyclic ring derivative and organic electroluminescent element comprising same | IDEMITSU KOSAN CO., LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-9126943-B2 | Nitrogenated heterocyclic ring derivative and organic electroluminescent element comprising same | IDEMITSU KOSAN CO., LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8501747-B2 | Functionally selective alpha2C adrenoreceptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120132899-A1 | NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120132899-A1 | NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | L3MBTL1 2087/4885SRC 2811/4885NUDT1 1603/4885 |
| US-20120132899-A1 | NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | H1-2, L1CAM, H1-0 | L3MBTL1 758/4885SRC 3223/4885NUDT1 1543/4885 |
| US-20150322074-A1 | 4-FLUOROPIPERIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | L3MBTL1 4401/4885SRC 4154/4885NUDT1 2387/4885 |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | L3MBTL1 2183/4885SRC 2845/4885NUDT1 1714/4885 |
| US-20210087189-A1 | SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, SIK1 | L3MBTL1 3073/4885SRC 3194/4885NUDT1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.